COVID-19 took over the world in 2020 but getting reliable data to understand its effect on cancer takes time¡ªusually 2 to 3 years using traditional population-based data sources like state cancer registries.
Until data started becoming available, researchers had to find innovative ways to gather some facts.
These images and text are a sample of American Cancer Society (ÎÚÑ»´«Ã½) studies published in 2021 based on data found in both traditional and less familiar ways. They show the beginnings of how the COVID-19 pandemic is affecting the continuum of cancer care.
In less than 2 months?after the United States identified its first cases of COVID-19, there were?more than 100,000 cases?and?2,000 deaths.
Everyone attempted to prevent the virus from spreading:
Disruptions in health care have affected the full range of cancer care?and care for others who may have a higher risk for being hospitalized and dying from coronavirus infection. The pandemic has also increased the risk for people with cancer or with a history of it to have a?reduced quality of life?due to cancer worry, health anxiety, depression, and inactivity.
In most states, the COVID-19 pandemic hasn't helped increase the low lung-cancer screening rates of people eligible for a yearly low-dose computed tomography (LDCT).
Surprisingly, though, when ÎÚÑ»´«Ã½ researchers?compared screening rates between 2019 and 2020, they found?19 states had improved screening rates¡ªwith Kentucky having the most improvement.
"Kentucky's screening implementation efforts led to rates?more than 2 times the national average?and?4 times that of?West Virginia and Arkansas,?other high lung-cancer burden states.¡±
¡ªRobert Smith, PhD, study co-author and?ÎÚÑ»´«Ã½ Senior Vice President, Cancer Screening
?